文献速递甲状腺疾病

含碘塞罗宁的甲状腺功能减退症治疗与痴呆及死亡风险降低相关

Treatment of Hypothyroidism That Contains Liothyronine is Associated With Reduced Risk of Dementia and Mortality.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

结果显示联合治疗较左甲状腺素单药治疗的痴呆与死亡风险更低,但作者指出仍需进一步研究确认。

要点

  • 甲减患者即使TSH正常,痴呆风险约高1.4倍、死亡风险升高逾2.0倍,TSH偏离目标时最明显。
  • 倾向性评分匹配队列中,联合治疗较左甲状腺素单药治疗的痴呆风险低27%、死亡风险低31%。
  • 调整Cox模型显示联合治疗使痴呆风险降低16%、死亡风险降低25%。

核心结论

  • 尽管接受标准左甲状腺素(LT4)治疗,甲状腺功能减退症仍与痴呆和死亡风险升高相关。
  • 加用碘塞罗宁(T3)可能比单用LT4更有效地降低这些风险,但尚需进一步研究确认含T3方案的认知与生存获益。

研究设计与样本

  • 采用倾向性评分匹配平衡年龄、性别和合并症等协变量,并通过Cox比例风险模型获得调整后风险比。
  • 平行开展系统评价与Meta分析,纳入12项研究评估甲状腺功能减退症的痴呆风险。

主要发现

  • 甲状腺功能减退症患者痴呆风险约高1.4倍、死亡风险升高逾2.0倍,即使TSH正常亦如此,且TSH偏离目标时最为明显。
  • 平行Meta分析显示痴呆风险升高1.4倍。
  • 在倾向性评分匹配形成的左甲状腺素单药治疗与联合治疗对比队列中,相对风险分析显示联合治疗的痴呆风险低27%、死亡风险低31%。
  • 调整Cox模型(风险比)显示联合治疗患者痴呆风险降低16%、死亡风险降低25%。

局限性

  • 作者指出,仍需进一步研究以确认含T3方案的认知与生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Standard levothyroxine (LT4) therapy may not fully address all risks associated with hypothyroidism-especially cognitive decline, dementia, and mortality-even when TSH levels are normalized. Observational studies link hypothyroidism to higher dementia rates; the role of LT4 plus T3 therapies remains uncertain. METHODS: This retrospective cohort study analyzed TriNetX data, comparing 1.26 million patients with hypothyroidism (on LT4, LT4 + T3, or desiccated thyroid extract) to 3.32 million controls. Outcomes included dementia, atrial fibrillation, and mortality over 20 years of follow-up. Propensity score matching was used to balance covariates for age, sex, and comorbidities. Adjusted hazard ratios were obtained via Cox proportional hazard modeling. A parallel systematic review and meta-analysis of 12 studies evaluated dementia risk in hypothyroidism. RESULTS: Patients with hypothyroidism showed a ∼1.4-fold higher risk of dementia and a >2.0-fold increase in mortality-even with normal TSH-and these risks were most pronounced when TSH levels were off-target. A parallel meta-analysis indicated a 1.4-fold heightened dementia risk. In cohorts formed by propensity score matching comparing LT4 monotherapy vs combination therapy, relative risk analysis indicated 27% and 31% lower dementia and mortality risks, respectively, with combination therapy. The adjusted Cox model (hazard ratio) showed 16% and 25% reductions in these outcomes for combination therapy patients. CONCLUSION: Despite standard LT4 therapy, hypothyroidism remains associated with heightened risks of dementia and mortality. Adding T3 may more effectively mitigate these risks than LT4 alone, but further studies are needed to confirm the cognitive and survival benefits of T3-containing regimens.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Beltrão FEL, Carvalhal G, Meneghini V, et al. Treatment of Hypothyroidism That Contains Liothyronine is Associated With Reduced Risk of Dementia and Mortality. J Clin Endocrinol Metab. 2026. PMID: 40579157. doi:10.1210/clinem/dgaf367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。